APA

Tentori L., Muzi A., Dorio A. S., Scarsella M., Leonetti C., Shah G. M., Xu W., Camaioni E., Gold B., Pellicciari R., Dantzer F., Zhang J. & Graziani G. (20100805). Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. : Current cancer drug targets.

Chicago

Tentori L, Muzi A, Dorio A S, Scarsella M, Leonetti C, Shah G M, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J and Graziani G. 20100805. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. : Current cancer drug targets.

Harvard

Tentori L., Muzi A., Dorio A. S., Scarsella M., Leonetti C., Shah G. M., Xu W., Camaioni E., Gold B., Pellicciari R., Dantzer F., Zhang J. and Graziani G. (20100805). Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. : Current cancer drug targets.

MLA

Tentori L, Muzi A, Dorio A S, Scarsella M, Leonetti C, Shah G M, Xu W, Camaioni E, Gold B, Pellicciari R, Dantzer F, Zhang J and Graziani G. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent. : Current cancer drug targets. 20100805.